| Literature DB >> 33985825 |
Alicia Clark1, Sierra Bonilla1, Dingjie Suo1, Yeruham Shapira2, Michalakis Averkiou3.
Abstract
High-intensity focused ultrasound (HIFU) is a non-invasive tool that can be used for targeted thermal ablation treatments. Currently, HIFU is clinically approved for treatment of uterine fibroids, various cancers, and certain brain applications. However, for brain applications such as essential tremors, HIFU can only be used to treat limited areas confined to the center of the brain because of geometrical limitations (shape of the transducer and skull). A major obstacle to advancing this technology is the inability to treat non-central brain locations without causing damage to the skin and/or skull. Previous research has indicated that cavitation-induced bubbles or microbubble contrast agents can be used to enhance HIFU treatments by increasing ablation regions and shortening acoustic exposures at lower acoustic pressures. However, little research has been done to explore the interplay between microbubble concentration and pressure amplitude on HIFU treatments. We developed an in vitro experimental setup to study lesion formation at three different acoustic pressures and three microbubble concentrations. Real-time ultrasound imaging was integrated to monitor initial microbubble concentration and subsequent behavior during the HIFU treatments. Depending on the pressure used for the HIFU treatment, there was an optimal concentration of microbubbles that led to enhanced heating in the focal area. If the concentration of microbubbles was too high, the treatment was detrimentally affected because of non-linear attenuation by the pre-focal microbubbles. Additionally, the real-time ultrasound imaging provided a reliable method to monitor microbubble activity during the HIFU treatments, which is important for translation to in vivo HIFU applications with microbubbles.Entities:
Keywords: Acoustic shadowing; Bubble-enhanced heating; High-intensity focused ultrasound; Inertial cavitation; Ultrasound contrast agents
Mesh:
Year: 2021 PMID: 33985825 PMCID: PMC8243806 DOI: 10.1016/j.ultrasmedbio.2021.03.035
Source DB: PubMed Journal: Ultrasound Med Biol ISSN: 0301-5629 Impact factor: 3.694